Suppr超能文献

Tenckhoff导管更换或腹腔内使用尿激酶:复发性持续性非卧床腹膜透析(CAPD)腹膜炎管理的随机试验

Tenckhoff catheter replacement or intraperitoneal urokinase: a randomised trial in the management of recurrent continuous ambulatory peritoneal dialysis (CAPD) peritonitis.

作者信息

Williams A J, Boletis I, Johnson B F, Raftery A T, Cohen G L, Moorhead P J, el Nahas A M, Brown C B

机构信息

Sheffield Regional Renal Unit, Royal Hallamshire Hospital, UK.

出版信息

Perit Dial Int. 1989;9(1):65-7.

PMID:2488185
Abstract

A randomised trial, comparing Tenckhoff catheter replacement as a one-stage procedure and i.p. urokinase, was undertaken in the management of recurrent continuous ambulatory peritoneal dialysis (CAPD) peritonitis. In addition to appropriate i.p. antibiotic treatment, 17 patients received i.p. urokinase (5000 i.u.) on the second and fourth days of antibiotic treatment, and 14 patients underwent CAPD catheter replacement. An additional six patients also underwent catheter replacement following the recurrence of peritonitis after urokinase treatment. The subsequent recurrence rate of peritonitis following CAPD catheter replacement (5%) was significantly less than after urokinase (41%) (p less than 0.001). Fourteen patients remained free of peritonitis for at least three months after catheter replacement, and five patients were peritonitis-free following urokinase for this period.

摘要

一项随机试验对将Tenckhoff导管置换作为一期手术与腹腔内使用尿激酶治疗复发性持续性非卧床腹膜透析(CAPD)腹膜炎的效果进行了比较。除了适当的腹腔内抗生素治疗外,17例患者在抗生素治疗的第二天和第四天接受了腹腔内尿激酶治疗(5000国际单位),14例患者接受了CAPD导管置换。另有6例患者在尿激酶治疗后腹膜炎复发,随后也接受了导管置换。CAPD导管置换后腹膜炎的后续复发率(5%)显著低于尿激酶治疗后(41%)(p<0.001)。14例患者在导管置换后至少三个月无腹膜炎复发,5例患者在此期间接受尿激酶治疗后无腹膜炎复发。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验